T cell receptor gene transfer to target the Epstein-Barr virus-associated malignancy nasopharyngeal carcinoma

Y Zheng, Lee Machado, B Johnson, C James, Greg Parsonage, S P Lee

Research output: Contribution to ConferenceAbstract


Epstein-Barr Virus (EBV)-positive post-transplant lymphoproliferative disease (PTLD) can be successfully treated by infusing T cells reactivated in vitro with EBV-transformed B lymphoblastoid cell lines (LCLs). T cell lines generated in this way are dominated by reactivities to the EBNA 3 viral proteins. However, such an approach may not be appropriate to treat other more common EBV-associated malignancies since, unlike PTLD, these tumours do not express the immunodominant EBNA 3 proteins; instead viral protein expression is restricted to relatively weak antigens. Furthermore, generating such T cell lines can take many weeks of in vitro culture. T cell receptor (TCR) gene transfer offers an alternative approach whereby T cells of defined specificity can be generated rapidly and reliably from all patients. We are exploring this method to treat undifferentiated Nasopharyngeal carcinoma (NPC), a tumour that occurs at high frequency in Southeast Asia (incidence >20/100,000 population) and where >50% of cases express the EBV protein LMP2. To ensure TCR gene transfer could be widely applicable to treat this cancer we have focussed on the T cell response to an LMP2 epitope that is restricted through HLA A*1101, an allele carried by >50% of the Chinese population. Furthermore the target epitope sequence is conserved in EBV strains present in NPC tumours. Having generated a high avidity T cell clone specific for this epitope the genes encoding the TCR a and b chain were cloned into the same MP71 retroviral vector, separated by a self-cleaving 2A peptide to ensure equal expression. Retrovirus was generated using Phoenix A packaging cells and following stimulation with anti-CD3 antibody, T cells from five A*1101+ donors (including an NPC patient) were transduced with this virus. Three days later, HLA:peptide pentamer staining detected the transferred TCR in 12-17% of CD8+ T cells. Staining for the b chain indicated that mispairing with endogenous a chains can occur in 0-8% of T cells. The TCR-transduced T cells expanded rapidly in vitro in response to antigen, showed high avidity for the target peptide (10-10M), and lysed autologous fibroblasts expressing LMP2. Significantly, they also recognised EBV-transformed LCLs which express physiological levels of LMP2 in an HLA A*1101-restricted manner. Preliminary data indicate that some CD4+ T cells transduced with this TCR also recognised A11.01+ LCLs suggesting they might provide a helper function in vivo to aid persistence of LMP2-specific CD8+ effectors.
Original languageEnglish
Publication statusPublished - 1 Jan 2009
EventNational Cancer Research Institute (NCRI) Cancer Conference - University of Birmingham, Birmingham, United Kingdom
Duration: 6 Nov 20169 Nov 2016


ConferenceNational Cancer Research Institute (NCRI) Cancer Conference
CountryUnited Kingdom
Internet address

Fingerprint Dive into the research topics of 'T cell receptor gene transfer to target the Epstein-Barr virus-associated malignancy nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this